Science & Enterprise subscription

Follow us on Twitter

  • Results from a clinical trial show a combination of two synthetic antibodies reduces deaths in hospitalized Covid-1… https://t.co/AtztCHfZLl
    about 7 hours ago
  • New post on Science and Enterprise: Antibodies Help Some Hospitalized Covid-19 Patients https://t.co/lJhns0fZzJ #Science #Business
    about 7 hours ago
  • https://t.co/BUeUy0ajO3 ... Crocodile on the Tarcoles River in Costa Rica, for #NaturePhotographyDay ... February 2020.
    about 1 day ago
  • https://t.co/mtU98giel5 Oystercatcher for #NaturePhotographyDay ... Cape May, New Jersey. June 2019.
    about 1 day ago
  • Two biotechnology companies are designing therapies to deliver edited genes to treat Friedreich’s ataxia and amyotr… https://t.co/7tbDhyf5lv
    about 1 day ago

Please share Science & Enterprise

Synthetic Bio Company Goes Public in $2.5B Merger

Investment graphic

A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition. . . . → Read More: Synthetic Bio Company Goes Public in $2.5B Merger

AI Drug Discovery Company Acquired in $270M Deal

Four fist bump

A biotechnology company using protein dynamics to develop precision cancer therapies is acquiring a drug discovery company based on machine learning algorithms. . . . → Read More: AI Drug Discovery Company Acquired in $270M Deal

Molecular Diagnostics Company Acquired in $1.8B Deal

Investment graphic

GenMark Diagnostics, a developer of diagnostics systems using genomic analysis, was acquired by drug maker Roche in a deal valued at $1.8 billion. . . . → Read More: Molecular Diagnostics Company Acquired in $1.8B Deal

Gene-Editing Biotech Acquires DNA Bar Code Company

DNA chip graphic

A developer of therapies using highly precise gene editing is acquiring a company delivering gene therapies identified with DNA bar codes. . . . → Read More: Gene-Editing Biotech Acquires DNA Bar Code Company

Cannabidiol Drug Maker Acquired in $7.2B Deal

Cannabis plant

A developer of treatments for rare neurological diseases derived from cannabis is being acquired by Jazz Pharmaceuticals in a $7.2 billion deal. . . . → Read More: Cannabidiol Drug Maker Acquired in $7.2B Deal

2020 Venture Funds Mixed, Biotech Keeps Sizzling

2020 venture transactions

Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling

Neuroscience Biotech Acquired in $770M Deal

Brain activity graphic

A three year-old biotechnology company developing treatments for psychiatric and movement disorders is being acquired by global drug maker Novartis. . . . → Read More: Neuroscience Biotech Acquired in $770M Deal

Oral Drug Delivery Company Acquired in $1.8B Deal

Investor screen

Emisphere Technologies, developers of a process that makes biologic drugs available as oral medicines is being acquired by drug maker Novo Nordisk. . . . → Read More: Oral Drug Delivery Company Acquired in $1.8B Deal

Venture Rounds, IPOs, Mergers Vanish in Election Week

White House

Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week

Bayer Gains Gene Therapy Biotech in $4B Deal

AskBio Bioreactor

Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders. . . . → Read More: Bayer Gains Gene Therapy Biotech in $4B Deal